| Transgenic expression of IL15 improves antiglioma activity of IL13Rα2-CAR T cells but results in antigen loss variants G Krenciute, BL Prinzing, Z Yi, MF Wu, H Liu, G Dotti, IV Balyasnikova, ... Cancer immunology research 5 (7), 571-581, 2017 | 266 | 2017 |
| Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity B Prinzing, CC Zebley, CT Petersen, Y Fan, AA Anido, Z Yi, P Nguyen, ... Science translational medicine 13 (620), eabh0272, 2021 | 147 | 2021 |
| Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma Z Yi, BL Prinzing, F Cao, S Gottschalk, G Krenciute Molecular Therapy Methods & Clinical Development 9, 70-80, 2018 | 111 | 2018 |
| RASA2 ablation in T cells boosts antigen sensitivity and long-term function J Carnevale, E Shifrut, N Kale, WA Nyberg, F Blaeschke, YY Chen, Z Li, ... Nature 609 (7925), 174-182, 2022 | 72 | 2022 |
| MyD88/CD40 signaling retains CAR T cells in a less differentiated state B Prinzing, P Schreiner, M Bell, Y Fan, G Krenciute, S Gottschalk JCI insight 5 (21), 2020 | 37 | 2020 |
| CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing? BL Prinzing, SM Gottschalk, G Krenciute Expert review of anticancer therapy 18 (5), 451-461, 2018 | 21 | 2018 |
| Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci. Transl. Med. 13, eabh0272 B Prinzing, CC Zebley, CT Petersen, Y Fan, AA Anido, Z Yi, P Nguyen, ... | 11 | 2021 |
| Hypoxia-inducible CAR expression: An answer to the on-target/off-tumor dilemma? B Prinzing, G Krenciute Cell Reports Medicine 2 (4), 2021 | 7 | 2021 |
| Transgenic expression of IL15 improves antiglioma activity of IL13Ralpha2-CAR T cells but results in antigen loss variants. Cancer Immunol Res 5 (7): 571–581 G Krenciute, BL Prinzing, Z Yi, MF Wu, H Liu, G Dotti, IV Balyasnikova, ... CIR-16-0376, 2017 | 7 | 2017 |
| De novo DNA methylation programs regulate CAR T-cell exhaustion CC Zebley, CT Petersen, B Prinzing, M Bell, Y Fan, JC Crawford, H Houke, ... The Journal of Immunology 204 (1_Supplement), 246.5-246.5, 2020 | 5 | 2020 |
| DNMT3A-Dependent Epigenetic Programs Constrain CAR T Cell Survival and Effector Function B Prinzing, CC Zebley, CT Petersen, M Bell, Y Fan, JC Crawford, H Houke, ... Molecular Therapy 28 (4), 43-43, 2020 | 1 | 2020 |
| Chimeric Antigen Receptors with a MyD88 and CD40 Endodomain Endow T Cells with Superior Antitumor Activity B Prinzing, M Bell, P Schreiner, Y Fan, G Krenciute, S Gottschalk MOLECULAR THERAPY 27 (4), 431-431, 2019 | 1 | 2019 |
| LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy S Mai, A Hodges, HM Chen, J Zhang, YL Wang, Y Liu, F Nakatsu, X Wang, ... Cancer research 83 (24), 4047-4062, 2023 | | 2023 |
| Chimeric myd88 receptors S Gottschalk, B Prinzing US Patent App. 17/918,644, 2023 | | 2023 |
| High-Affinity PD1-CD28 Chimeric Switch Receptors Enhance Costimulatory Signaling and Improve TCR and CAR T Cell Antitumor Activity B Prinzing, S Gottschalk MOLECULAR THERAPY 30 (4), 228-228, 2022 | | 2022 |
| Chimeric antigen receptors with myd88 and cd40 costimulatory domains S Gottschalk, B Prinzing, G Krenciute US Patent App. 17/056,181, 2021 | | 2021 |
| CHIMERIC ANTIGEN RECEPTORS WITH A MYD88 AND CD40 ENDODOMAIN ENDOW T CELLS WITH SUPERIOR ANTITUMOR ACTIVITY B Prinzing, G Krenciute, S Gottschalk HUMAN GENE THERAPY 29 (11), A6-A6, 2018 | | 2018 |
| Transgenic Expression of IL15 Improves Antiglioma Activity of IL13R alpha 2-CAR T Cells G Krenciute, B Prinzing, Z Yi, I Balyasnikova, G Dotti, S Gottschalk PEDIATRIC BLOOD & CANCER 64, S1-S1, 2017 | | 2017 |
| IMMU-17. TRANSGENIC EXPRESSION OF IL15 IMPROVES ANTIGLIOMA ACTIVITY OF IL13RΑ2-CAR T CELLS D Steffin, B Prinzing, Z Yi, I Balyasnikova, G Dotti, S Gottschalk, ... Neuro-Oncology 19 (suppl_4), iv31-iv31, 2017 | | 2017 |
| IMMU-20. SELECTING AN EPHA2-CAR FOR THE IMMUNOTHERAPY OF DIPG AND GBM B Prinzing, Z Yi, K Chow, S Gottschalk, G Krenciute Neuro-Oncology 19 (Suppl 4), iv32, 2017 | | 2017 |
